Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates.
Saved in:
| Title: | Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates. |
|---|---|
| Authors: | Koh, Jiwon1,2 (AUTHOR), Im, Seock-Ah2,3 (AUTHOR) moisa@snu.ac.kr |
| Source: | Cancer Research & Treatment. Jan2026, Vol. 58 Issue 1, p15-25. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
